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1. INTRODUCTION
jj The median age of CF diagnosis remains at 6 months, but the diagnostic yield in subjects 
older than 18 years has been increasing, probably due to improved clinical awareness and 
better access to 2nd-level testing. Switzerland introduced newborn screening for CF in 2011 
(IRT/DNA/IRT protocol), which may in time lead to earlier diagnosis, prompt management 
and better outcomes.
jj The diagnostic work-up of adults can be challenging because:
js some of the classic clinical characteristics of the disease may be absent 
js different cut-off values of diagnostic tests may apply 
js uncommon CFTR variants may be observed in those patients presenting with later onset 
disease, modifying the optimal approach to genetic testing
jj Diagnostic terminology is still evolving as our knowledge of the spectrum of CFTR disor-
ders increases. 
jj Several clinical entities associated with CFTR dysfunction but not fulfilling the diagnostic 
criteria for CF are called CFTR-related disorders (CFTR-RD). The best-recognized CFTR-
RD are: 
js congenital bilateral absence of the vas deferens (CBAVD) 
js acute recurrent or chronic pancreatitis 
js diffuse bronchiectasis
jj Terms such as “mild” or “atypical” CF may be misleading and it is best to classify patients 
where possible as having CF or CFTR-RD.  
2. SYMPTOMS AND CLINICAL FEATURES SUGGESTIVE OF CF OR CFTR-RD 
IN ADULTHOOD.
jj The spectrum of CF clinical features (Table 1) is broad characterized by varying degrees 
of organ involvement, disease severity and progression rate. 
3. DIAGNOSTIC WORK-UP  
In cases in which the clinical picture is suggestive of CF or CFTR-RD in an adult patient, dia-
gnosis should be established by specific laboratory tools such as:
jj The sweat chloride test
jj CFTR gene analysis
jj CFTR bioassays
Thoracic imaging, pulmonary function tests, fecal analysis of elastase or a spermogram, may sup-
port the initial clinical suspicion and characterize the phenotype and the severity of the disease.
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3.1 Sweat chloride test
jj It remains the gold standard of CF diagnosis and it should be performed in a spe-
cialized centre. 
jj Method: application of pilocarpine nitrate (cholinergic drug) on the skin, preferably the 
flexor surface of the forearm or alternatively the upper arm, thigh or calf → iontophoresis 
using two electrodes (one positive and one negative) and a gradually increasing current 
up to 4 mA for less than 5 min → the positively charged pilocarpine ions move away from 
the positive electrode and into the skin → intracellular Ca+2 concentration increases → 
opening of the calcium-activated Cl- channel → production and collection of sweat during 
20-30 min → sweat analysis of the concentration of Cl-.
js Sweat Cl- is increased in CF.
js Osmolality and conductivity have poor discriminatory power for the diagnosis of CF.
jj The lower limit of Cl- detection provided by the laboratory should be ≤ 10mmol/l, whereas 
the upper end of reportable results should be ≤160 mmol/l, as a higher concentration is 
not physiologically possible. 
 Table 1:  Symptoms and clinical features suggestive of CF or CFTR-RD in 
 adulthood (adapted from1-4)
Chronic sinopulmonary manifestations:
1. Airway colonization/infection with typical CF pathogens, including Staphylococcus  aureus, 
Haemophilus influenzae, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, 
Burkholderia cepacia complex, Achromobacter xylosoxidans
2. Symptoms: Chronic productive cough, haemoptysis associated with diffuse pulmonary 
disease in the absence of an alternative diagnosis
3. Persistent radiographic abnormalities (e.g. bronchiectasis, atelectasis, persistent infiltrates, 
hyperinflation, radiographic evidence of chronic pansinusitis)
4. Allergic bronchopulmonary aspergillosis (ABPA)
5. Obstructive airways disease 
6. Pansinusitis, nasal polyps 
7. Digital clubbing
Gastrointestinal and nutritional abnormalities
1. Intestinal: distal intestinal obstruction syndrome (DIOS)
2. Pancreatic : exocrine or endocrine pancreatic insufficiency, recurrent acute or chronic 
pancreatitis, pancreatic abnormalities on imaging 
3. Hepatic: chronic hepatic disease manifested by clinical or histological evidence of focal 
biliary cirrhosis or multilobular cirrhosis, primary sclerosing cholangitis
4. Nutritional: hypoproteinemia and oedema, complications secondary to fat-soluble vitamin 
deficiencies, osteopenia/osteoporosis diagnosed at <40 years of age
Salt loss syndromes: acute salt depletion, chronic metabolic alkalosis
Infertility in males: obstructive azoospermia due to congenital bilateral absence of the vas 
deferens (CBAVD)
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jj For an individual patient, results should always be interpreted within the clinical context 
and all positive tests must be confirmed by a second sweat Cl- test or by CFTR genetic 
testing.
jj The diagnosis of CF is supported by sweat Cl- levels ≥60 mmol/l. 
jj Diagnosis of CF is not supported when the sweat Cl- level is <60 mmol/l 
js Some CFTR variants, including some CF-causing variants, such as 3849+10kbC>T, 
2789+5G>A, R117H, R117L, A455E, A309D, G551S, IVS8 (5T), L206W, L997F, 
D1152H may result in a sweat Cl- <60 mmol/l when they are associated with another 
CFTR variant.
jj Current guidelines suggest that sweat Cl-<30 mmol/l is considered normal.
jj Values of sweat Cl- between 30-59 mmol/l are called “borderline” or “intermediate” values 
and indicate some degree of CFTR dysfunction. 
jj Causes, other than CF, that may lead to a false positive or false negative sweat test are 
presented in Tables 2 and 3 respectively. 
 Table 2:  Causes other than CF which may be associated with a false positive 
sweat Cl- test - in alphabetical order (Adapted from5-9)*
Likely
  Anorexia nervosa* 
  Arsenic toxicity 
  Atopic dermatitis* 
  Carbonic anhydrase XII mutations 
  Malnutrition (if severe) 
  Munchausen syndrome by proxy*
  Technical issues*
– Evaporation of sweat sample
– Application of amethocaine at the site of testing
  Topiramate therapy
Possible but further validation is required
  Ectodermal dysplasia
  Familial cholestasis 
  Fucosidosis type I
  Glycogen storage disease type I 
  Hypogammaglobulinemia  
  Hypoparathyroidism 
  Hypothyroidism (untreated)
  Pseudohypoaldosteronism
  Psychosocial failure to thrive
(continued)
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 Table 3:  Causes which may be associated with a false negative sweat Cl- test 
(Adapted from 5,7)*
Likely
  Technical factors*
– Sweat sample dilution
– Failure to dry skin before sweat collection
Possible but further validation is required
  Mineralocorticoid treatment
Unlikely**
  Young age
  Edema*
  Hypoproteinemia*
  Penicillin therapy
*Conditions that should always be considered.
** Some reports but very limited or insufficient/contradictory evidence
Unlikely**
  Autonomic dysfunction
  Celiac disease
  Glucose 6 phosphatase (G6PD) deficiency  
  KID syndrome
  Klinefelter syndrome
  Mauriac syndrome 
  Mucopolysaccharidosis type I 
  Nephrogenic diabetes insipidus 
  Prostaglandin E1 infusion
  Pyelonephritis
  Shwachman-Diamond syndrome   
  Systemic lupus erythematosus   
  Triosephosphate isomerase deficiency    
  Trisomy 21
  Untreated Addison’s disease
*Conditions that should always be considered.
** Some reports but very limited or insufficient/contradictory evidence.
3.2 CFTR genetic testing
jj DNA analysis should be performed in a specialized genetic laboratory. All CF/CFTR-RD 
patients should be genotyped. CFTR genetic testing is used for diagnostic confirmation, 
for accurate genetic counselling and for personalized treatment decisions (e.g. ivacaftor 
for gating variants such as G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, 
S549N, S549R, ivacaftor for the class IV variant R117H, ivacaftor/lumacaftor for F508del/
F508del) (See also Chapter “CFTR modifiers”).
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jj The diagnosis of CF is supported by the identification of two CF-causing genetic variants. 
jj The laboratory should report on relevant identified CFTR variants and make clear whether 
they are: a) CF-causing and predicted to be associated with CFTR residual function or not, 
b) of varying clinical consequences (VVCC) or c) of unknown significance (VUS). Variants
which are likely to have no clinical relevance are generally not reported. However, it must
be kept in mind that interpretation of clinically relevant genomic variation can be challen-
ging (see also Chapter “Pathogenesis of CF”).
jj The frequency of CF-causing variants in patients varies considerably according to ethnic 
origin. To adapt the genetic analysis and/or interpretation appropriately, it is important 
that the clinician asks the ethnicity of each parent and transmits the information 
to the laboratory. 
jj Most commercially-available first-level screening assays test 30-50 CF-causing va-
riants. In Switzerland, their sensitivity to detect CF alleles is 85-90% based on ethnic back-
ground. Such tests allow detection of: 
js both (2/2) disease-causing variants in 70-80% of CF patients 
js 1/2 in 20-30% of patients 
js 0/2 in 1-2% of patients (false-negative result)
jj In some clinical situations (e.g. when only one variant is identified by first-level screening), 
second-level testing with high-sensitivity analysis of the entire CFTR gene may be 
necessary.  
js Gene sequencing has a sensitivity of ≥98%, but is more expensive than first-level 
screening. 
js Some common variants are not routinely detected by sequencing analysis and should 
be specifically tested when appropriate (e.g. the Eastern European dele2,3 deletion and 
the Hispanic 1811+1.6kbA>G intronic variant). 
js Gene deletions and duplications (1-5% of CF alleles) are not detected by sequencing; 
further testing by MLPA or other techniques may be necessary. 
js Second-level testing can identify variants of unknown significance; the laboratory should 
provide the most accurate possible interpretation. 
jj Whenever two potentially disease-causing variants are detected, cis or trans phase (see 
Chapter “Pathogenesis of CF”, section “Complex alleles”) should be determined. 
This is especially true for variants of varying clinical consequences (VVCC), whose roles 
are often unclear. Ideally, phase is determined by family testing (e.g. parents) whereas 
in some cases it can be probabilistic (e.g. F508del and R117H are essentially certain to 
be in trans).
jj In case of a strong clinical suspicion of CF but without confirmation by the presence of two 
disease-causing CFTR variants, firstly the genetic testing should be re-evaluated (“was it 
sufficiently sensitive?”). If this was the case, genetic heterogeneity could be considered: 
although such cases are extremely rare, other genes than CF could be responsible for a 
clinical phenotype of CF. However, at present no reliable testing exists for such forms.
jj Genetic testing laboratories should provide results within a defined and appropriate turna-
round time (TAT). TAT for routine testing should be <1 week and <2 weeks for 1st- and 
2nd- level testing respectively. Urgent requests should generally be reported in ≤3 working 
days (both levels). 
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jj Reimbursement and insurance issues
js Swiss obligatory health insurance reimburses the cost of laboratory tests which “serve 
to diagnose or treat a disease and its consequences” (LAMal Art 25. Al.1) when the 
disease is included in the Analysis List, as is the case for both cystic fibrosis (“fibrose 
kystique”, “Cystische Fibrose”) and CAVD (“Aplasie congénitale du canal deferent”, 
“Congenitale Aplasie des Vas Deferens”). 
js Carrier testing, for example in relatives of CF patients or partners of CF patients or 
known carriers, is not reimbursed by obligatory health insurance. However, this is not a 
reason to avoid discussing carrier testing when medically recommended. 
js Patients should be aware that obtaining private insurance can be difficult or expensive 
after the diagnosis of CF.
js The costs of 1st- and 2nd-level testing vary according to the exact techniques used but 
are approximately 550 CHF and 1’700-3’000 CHF at the time of writing; carrier testing 
typically costs between 350-550 CHF. The laboratory can provide accurate costs for 
individual situations.
jj Post-test counselling and cascade testing
js All individuals who test positive for one or two CF-causing variants must be 
 offered genetic counselling to explain the eventual reproductive and/or familial conse-
quences of the result. Counselling should be timely, taking into account the fact that re-
latives as well as the patient are potentially at increased risk of having offspring with CF.
js Genetic counselling and “cascade” carrier testing should be offered to all relatives 
of individuals with CF-causing variants. As stated above, the fact that carrier testing 
is not obligatorily reimbursed by health insurance is not a justification for not offering 
counselling/testing.
js Carrier testing should not be automatically offered for variants of varying clinical conse-
quences (VVCC), because of their reduced penetrance and clinical variability. However, 
genetic counselling should always be an option, and clinical judgement should be used 
to decide when testing is appropriate.
Note: prenatal diagnosis for CFTR-RD genotypes is not generally considered appropriate 
and should not be routinely offered.
jj Informed consent (Table 4). 
 Table 4:  Facts and recommendations concerning informed consent before 
 genetic testing for CF or CFTR-RD
Informed consent is required before all genetic testing (Federal Law on Human Genetic 
Analysis)
It is the responsibility of the physician requesting the test to ensure that appropriate counsel-
ling is provided and that consent is given
Oral consent is sufficient for diagnostic testing; the doctor should make a written note, for 
example “the patient was counselled and consent was given”
Written consent is obligatory before prenatal, pre-symptomatic and carrier testing
Parents or guardians must consent for persons unable to give informed consent (e.g. children).
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3.3 CFTR bioassays 
jj Bioassays provide direct evidence of CFTR dysfunction. At the time of writing these tests 
are not available in Switzerland.
jj Nasal potential difference (NPD) measurement (in vivo): 
js It is based on the observation that bioelectric potential differences across respiratory 
epithelia are abnormal in CF patients.
js Voltage differences are measured between two electrodes: the exploring electrode 
which rests on the top of the nasal mucosa and the reference electrode which is placed 
under the forearm skin. 
js Sequential application of 5 different solutions on the nasal mucosa: 1) Ringer’s solu-
tion, 2) Ringer’s solution and amiloride (ENaC inhibition), 3)chloride-free solution and 
 amiloride (Cl- secretion mediated by the activation of CFTR, Ca+2 dependent Cl- chan-
nels and ORCC), 4) chloride-free solution, amiloride and isoproterenol (further increase 
of CFTR mediated Cl- transport), 5) chloride-free solution, amiloride and ATP (activation 
of Cl- secretion through calcium-activated chloride channels).
js Compared to normal subjects, the typical pattern observed in CF consists of a more 
negative basal NPD, an exaggerated response to amiloride and no response to the 
Cl- free+amiloride+ isoproterenol solution. Figures S1-S3 of the Supplement show 
examples of NPD measurements in a healthy control and a CF patient. 
js Standard operating procedures (SOPs) are available for NPD. However, the test has 
several technical challenges and it is important to be performed by an experienced 
operator. Patient-related factors that can affect CFTR response should also be conside-
red (e.g. smoking, acute rhinitis within 2 weeks prior to the study, allergic rhinitis within 
a month prior to the study, polyp removal, certain drugs such as amiloride, hypertonic 
saline, inhaled antibiotics, DNAse).  
js Interpretation of NPD: The parameter used the most is the change in potential difference 
between the application of solution 3 (chloride-free solution + amiloride) and 4 (chlo-
ride-free solution + amiloride + isoproterenol). This difference is called ΔPD0CI/Iso (Iso 
referring to isoproterenol). Although there is no wide consensus regarding the cut-off 
points, the following categories have been used in the literature for ΔPD0CI/Iso
 – i) normal <-12 mv,
 – ii) abnormal >-7.7 mV and
 – iii) intermediate between -12 and -7.7mV.
Measurements are performed in both nostrils. Currently the mean ΔPD0CI/Iso is used for 
diagnostic purposes but this approach may underestimate CFTR function. A recent 
study suggested that the best ΔPD0CI/Iso value should also be taken into consideration. 
Figure S1b of the Supplement shows an example of how ΔPD0CI/Iso is measured on 
an NPD curve. 
jj Intestinal current measurement (ICM) (ex vivo): 
js It is based on the observation that bioelectric potential differences across intestinal 
epithelia are abnormal in CF patients.
js Freshly obtained suction rectal biopsies (minimally invasive procedure) → intestinal tis-
sue specimen is placed in mini-Ussing chambers → application of amiloride (to block 
ENaC) and stimulation with CFTR activatory agents → ion transport → measurement 
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of the transepithelial short-circuit current or potential difference → evaluation of CFTR 
function. 
js It has been mainly used in research, however increasing evidence suggests that it may 
be a useful tool in clinical practice and that it may be superior to NPD.
js Currently there are 2 different SOPs available (not standardized across laboratories).
jj β-adrenergic sweat secretion test (in vivo): 
js Assessment of sweat gland CFTR activity using an evaporimeter, to measure the rate of 
CFTR-mediated sweat secretion.
js Sequential intracutaneous administration in the forearm of the following solutions: car-
bachol (induction of cholinergic secretion) → atropine (inhibition of cholinergic secre-
tion) → solution containing atropine, isoproterenol, aminophylline (pure β-adrenergic 
secretion).
js Measurement of the mean maximal β-adrenergically stimulated sweat rate is a) absent 
in CF, b) reduced or absent in CFTR-related disorder, c) half the rate of healthy controls 
in cases of heterozygotes and d) equal to cholinergic sweat rate in healthy controls 
(examples in Figure S4 of the Supplement).
jj Intestinal organoids (ex vivo): 
js This technology was first described in 2013. It is a quantitative assay for CFTR function 
and, and although it is currently a research tool, it is considered to be very promising 
not only for diagnosis but also for CFTR-specific drug development (see also Chapter 
“CFTR modifiers”). 
js Suction rectal biopsies (minimally-invasive procedure) → Primary intestinal culture, 
intestinal stem cells proliferate under the effect of growth factors → they expand into 
closed organoids which are similar to in vivo tissue structures (crypt-like structures and 
internal lumen lined by differentiated cells, CFTR expressed at the apical membrane of 
the crypt cells) → When forskolin is applied to organoids derived from healthy controls, 
it induces rapid organoid swelling but its effect is strongly reduced in CFTR-deficient 
organoids → drug-induced restoration of CFTR-function can be assessed with this 
technique. 
4. DIAGNOSTIC TERMINOLOGY
jj The diagnostic terminology is still evolving as our knowledge of the spectrum of CFTR 
dysfunction increases.
jj Established CF diagnosis: 1) clinical features of CF in at least one organ and 2) CFTR 
dysfunction demonstrated through any of the following 
js Sweat chloride ≥60 mmol/l (repeated twice) or
js Two CF-causing variants in trans (i.e. in each CFTR gene) or
js An abnormal functional testing (NPD or ICM) characteristic of CF
jj CFTR-RD: clinical entities that are associated with CFTR dysfunction but do not 
fulfil the diagnostic criteria of CF; they are characterized by clinical features and fin-
dings of CFTR dysfunction and none or one CF causing variant. The best-recognized 
CFTR-RD are: 
js congenital bilateral absence of the vas deferens (CBAVD) 
js idiopathic chronic pancreatitis 
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js diffuse bronchiectasis
Note: According to the 2001 WHO classification, CFTR-RD includes isolated obstruc-
tive azoospermia, chronic pancreatitis, allergic bronchopulmonary aspergillosis, dis-
seminated bronchiectasis, diffuse panbronchiolitis, sclerosing cholangitis, neonatal 
hypertrypsinogenaemia.
5. DIAGNOSTIC ALGORITHMS 
jj The algorithms intended for the diagnosis of CF recommend specific reasoning pathways 
for the establishment of the diagnosis in clinically suspected cases of CF. 
jj The algorithm of the Swiss adult CF centres is an adaptation of the European, and 
the 2008 and 2017 CF Foundation algorithms. It presents the pathway of investiga-
tions performed in patients referred to Swiss Adult CF centres based on available 
diagnostic tests (Figure 1). Both sweat test and DNA analysis are proposed in suspec-
ted cases to allow further cascade screening of the patients’ relatives and personalized 
treatment decisions. Functional testing is proposed in selected cases at the last step, as 
these tests are not currently available in Switzerland.
jj The major differences between these algorithms are presented in Table 5. 
6. EXAMPLES OF CASES
jj Example 1: 1) absence of phenotypic characteristics of CF or CFTR-RD, 2) normal sweat 
chloride test and 2) one CF-causing variant. Diagnosis: healthy carrier.
jj Example 2: 1) at least one phenotypic characteristic of CF, 2) 2 CF-causing variants (one 
on each CFTR gene) and 3) a sweat Cl- concentration > 60 mmol/l. Diagnosis: CF. 
jj Example 3: 1) at least one phenotypic characteristic of CF, 2) detection of two CF-causing 
variants (one on each CFTR gene) and 3) a normal (<30 mmol/l) or borderline (30-59 
mmol/l) sweat Cl- concentration. Diagnosis: CF.
jj Example 4: 1) At least one phenotypic characteristics of CF, 2) one CF-causing and one 
variant of varying clinical consequences (such as VVCC associated with CFTR-RD) in trans 
and 3) a borderline (30-59 mmol/l) sweat chloride concentration. Diagnosis: CFTR-RD. 
jj Example 5: 1) at least one phenotypic characteristic of CF, 2) a borderline sweat Cl- 
concentration (30-59 mmol/l) and 3) one CF-causing variant in the 1st level genetic analysis 
→ Subsequent confirmation of only one CF-causing variant with 2nd level genetic analysis 
(gene sequencing). Diagnosis: CFTR-RD. Consider performing NPD or ICM (if available). 
jj Example 6: 1) Phenotypic characteristics highly suggestive of CF, 2) no detection of CF-
causing variants after 1st level and 2nd level genetic analysis and 3) sweat chloride test 
normal (<30 mmol/l)
js DNA sequencing is recommended, with testing for intronic variants and/or deletions and 
insertions of one or more exons of the CFTR gene. 
js NPD or ICM is recommended to document CFTR dysfunction. 
js Although very rare, genetic heterogeneity cannot be excluded since the CF phenotype 
could conceivably be caused by a genetic factor other than CFTR (if, as mentioned 
above, the sweat Cl- test is normal).
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 Table 5: Major differences among different algorithms for the diagnosis of CF and CFTR-RD in adults1-3,10-13
European guideline 
(2006)1
CF Foundation 
 guideline (2008)3
CF Foundation guideline 
(2017)2
Swiss adult CF centres 
 recommendations (2017)
Diagnostic 
categories
• Classic CF
• CFTR dysfunction
• Inconclusive
• CF unlikely
• CF
• CFTR-related
disorder
• Inconclusive
• CF unlikely
• CF
• CFTR-related disorder (not
in the algorithm)
• Not resolved
• CF unlikely
• CF
• CFTR-related disorder
• Inconclusive
• CF unlikely
Definition of 
CFTR-RD 
The term CFTR-
dysfunction is used. 
Non-classic CF or single 
organ phenotype asso-
ciated with CFTR muta-
tions (WHO diagnostic 
list)*1
0-1 CF-causing
mutations and clini-
cal signs (possibly
multiple-organ)
suggestive of CF
A symptomatic entity that 
does not meet diagnostic 
criteria for CF
Clinical entities that are 
associated with CFTR dys-
function but do not fulfil the 
diagnostic criteria of CF; 
clinical findings of CFTR 
dysfunction and 0-1 CF 
causing variant
Initial testing 
(algorithm entry)
Sweat chloride or CFTR 
genotyping
Sweat chloride Sweat chloride Sweat chloride and 1st level 
CFTR genotyping 
Sweat chloride 
upper limit of nor-
mal for no disease
30 mmol/l 30 mmol/l at an age 
up to 6 months and 
40mmol/l thereafter
30 mmol/l 30 mmol/l
(continued)
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panel
Variants that reflect the 
distribution and fre-
quency in the appropriate 
population
23 variants esta-
blished by the 
American College of 
Medical Genetics
Use CFTR2 mutation list, with 
guidelines given for muta-
tions not included in CFTR2*2
First-level screening assays 
test 30-50 CF-causing 
variants.
Adaptation of variant testing 
according to ethnicity.
CFTR variant 
categories
• CF-causing
• Involved in CFTR
related disease
• Not disease causing
• Unknown functional
consequences
• CF-causing
• No resulting clini-
cal effect
• Unknown functio-
nal consequences
• CF-causing
• Mutation of varying clinical
consequences (MVCC)
• Non-CF-causing
• Unknown functional
consequences
• CF-causing
• Variant of varying clinical
consequences (VVCC)
• No clinical
consequences
• Variant of unknown signi-
ficance (VUS)
CFTR functional 
testing in the 
algorithm
NPD NPD NPD/ICM NPD/ICM - Currently not 
available in Switzerland 
*1 Refers to the 2001 WHO classification that includes: isolated obstructive azoospermia, chronic pancreatitis, allergic bronchopulmonary aspergillosis, disseminated bronchiec-
tasis, diffuse panbronchiolitis, sclerosing cholangitis, neonatal hypertrypsinogenaemia
*2  Clinical and Functional Translation of CFTR project accessible in http://www.cftr2.org/index.php
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Figure 1: Algorithm for the diagnosis of CF and CFTR-related disorders in adults, 
in Switzerland 
CFTR genetic analysis should be performed in specialized laboratories and interpretation of the results should be done by an 
experienced geneticist. 
First level genetic testing refers to commercially-available assays testing for 30 to 50 CF-causing variants. 
Second level genetic testing refers to high-sensitivity analysis of the entire CFTR gene, notably gene sequencing or addi-
tional techniques whenever necessary (e.g. MLPA, specific research of some suspected variants that are not identified with 
gene sequencing – see text). 
The term VVCC refers to variants of varying clinical consequences. 
The terms “CF?” and “CFTR-RD?” are used to characterize cases that do not fulfil the diagnostic criteria for CF or CFTR-RD 
respectively, but present evidence of CFTR dysfunction. For these patients a close follow-up is recommended to timely identify 
the development of clinical features compatible with CF or CFTR-RD.
*a Whenever two potentially disease-causing variants are detected, phase (cis or trans) should be determined. This is especially 
true for variants of varying clinical consequences, whose roles are often unclear. Ideally, phase is determined by family testing
(e.g. parents) whereas in some cases it can be probabilistic (e.g. F508del and R117H are essentially certain to be in trans).
*b CFTR variants, such as 3849+10kbC>T, 2789+5G>A, R117H, R117L, A455E, A309D, G551S, IVS8 (5T), L206W, L997F,
D1152H, that result in sweat Cl- levels <60 mmol/l when they are associated with another CFTR variant, should be considered 
when interpreting sweat test results. 
*e CFTR bioassays are not available in Switzerland at the moment of writing.
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Figure S1: a) Nasal potential difference measurement (NPD) in a control (blue 
line) and a CF patient (red line), measured during sequential application of 5 
different solutions on the nasal mucosal. Note that the y axis has negative values. 
Compared to normal subjects, the typical pattern observed in CF consists of a 
more negative basal NPD, an exaggerated response to amiloride and no response 
to the isoproterenol solution. Solution 2 causes ENaC-inhibition, solution 3 acti-
vates CFTR, Ca+2 dependent Cl- channels and ORCC, solution 4 increases further 
CFTR-mediated Cl- transport and solution 5 activates calcium-activated chloride 
channels.  b) The parameter used the most is the ΔPD0CI/Iso (i.e. change in potential 
difference between the mucosal perfusion with solution 3 and solution 4). Figure 
S1b shows an example of how ΔPD0CI/Iso is measured on an NPD curve. Although 
there is no wide consensus regarding the cut-off points, <-12 mV is considered 
normal, >-7.7 mV abnormal and  values between -12 and -7.7mV intermediate. 
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Figure S2: Example of NPD measurement in a healthy control a) right nostril, 
b) left nostril.
(Courtesy of Julie Avolio RN and Dr Tanja Gonska, Program of Physiology and
Experimental Medicine, Research Institute, the Hospital for Sick Children, Toronto, ON,
Canada)
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b)
Figure S3: Example of NPD measurement in a CF patient with a G551D/G551D 
 genotype a) right nostril, b) left nostril  
(Courtesy of Julie Avolio RN and Dr Tanja Gonska, Program of Physiology and 
Experimental Medicine, Research Institute, the Hospital for Sick Children, Toronto, ON, 
Canada)
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Figure S4: Example of a β-adrenergic sweat test in a) a healthy control, b) a hete-
rozygote and c) a CF patient. The rate of CFTR-mediated sweat secretion is mea-
sured with an evaporimeter. The mean maximal β-adrenergically stimulated sweat 
rate is absent in CF and half the rate of healthy controls in cases of heterozygotes.  
(Courtesy of Julie Avolio RN and Dr Tanja Gonska, Program of Physiology and Experimental 
Medicine, Research Institute, the Hospital for Sick Children, Toronto, ON, Canada)
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